Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2025-03-03), Procyon's Intrinsic Value: Projected FCF is $0.20. The stock price of Procyon is $0.18. Therefore, Procyon's Price-to-Intrinsic-Value-Projected-FCF of today is 0.9.
The historical rank and industry rank for Procyon's Intrinsic Value: Projected FCF or its related term are showing as below:
PCYN'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.4 Med: 1.08 Max: 1.69
Current: 0.9
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Procyon was 1.69. The lowest was 0.40. And the median was 1.08.
PCYN's Price-to-Projected-FCF is ranked better than 75.55% of 548
companies
in the Drug Manufacturers industry
Industry Median: 1.56
vs PCYN: 0.90
Procyon Intrinsic Value: Projected FCF Historical Data
The historical data trend for Procyon's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Procyon's Intrinsic Value: Projected FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procyon's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procyon's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Procyon's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Procyon's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.18
/
0.20359472237073
=
0.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procyon Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Procyon's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCYN has been successfully added to your 